Physician profile
Ryan John Lynch
NPI 1013038850
$8,530.25
in general payments reported to CMS, 2019-2025
51 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $155 · 2021: $1,152 · 2022: $1,544 · 2023: $1,554 · 2024: $1,633 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,657.84 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.05 | 2021-2025 | |
| Pfizer INC. | $1,034.20 | 2023-2025 | |
| Lilly USA, LLC | $759.93 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $725.70 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novo Nordisk INC | $562.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $388.17 | 2019-2024 | Aimovig, Evenity, Prolia |
| Ucb, INC. | $378.14 | 2021-2024 | Nayzilam, Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $324.07 | 2022 | |
| Supernus Pharmaceuticals, INC. | $302.21 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $292.57 | 2019-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $264.53 | 2021 | |
| Eisai INC. | $219.52 | 2021-2025 | |
| Neurelis, INC. | $217.54 | 2021-2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.03 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $160.11 | 2020-2025 | Proclaim, Freestyle Libre 3, Infinity |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.